But Novartis doesnt want to just be a me-too. Gal likens the situation with GLP-1s to whats happening in China, where a burst of innovation has led to concerns about the real gains being made there and whether many drugs are simply offering incremental improvements over existing options, particularly in oncology
It says diminished appetite suppression compared with earlier doses from the same pen can reflect degradation rather than the body's response, and warns against assuming treatment failure without consulting the provider
doi: 10.1002/1096-9861(20000925)425:3 3.0.CO;2-H 94 KruijverFPSwaabDF
Theres a pocket for momentos and three sheets of fun stickers to make the whole process more enticing
Fourth, although gut microbiota modulation is considered a primary mode of action for GLPs, it remains uncertain whether observed microbial shifts directly drive metabolic benefits
doi: 10.1111/dom.14890 Della Pepa G, Patrcio BG, Carli F, et al